China’s biotech sector is on the rise, offering cheaper healthcare products globally, but faces geopolitical challenges. The CR-CP Life Science Fund, with $170 million, backs successful companies like Legend Biotech. Multinationals are eyeing Chinese biotechs for cost efficiencies. China faces hurdles in becoming a global leader in life sciences. Liu aims to establish a new investment fund in Hong Kong for life sciences.

Read more at Yahoo Finance: China’s rise in biotech to potentially lower healthcare costs, life science investor says